Martin Carl Tammemagi

Martin Carl Tammemagi

Auto-generated profile, based on publicly available information

Martin Carl Tammemagi

Brock University, St. Catharines, Ontario, Canada

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AMAnnette McWilliams
Annette McWilliams
MTMartin C. Tammemagi
Martin C. Tammemagi
JMJohn R. Mayo
John R. Mayo
HRHeidi Roberts
Heidi Roberts
GLGeoffrey Liu
Geoffrey Liu
SLStephen Lam
Stephen Lam
Major issues in the implementation of screening for lung cancer by means of low-dose computed tomography (CT) are the definition of a positive result and the management of lung nodules detected on the scans. We conducted a population-based prospective study to determine factors predicting the probability that lung nodules detected on the first screening low-dose CT scans are malignant or will be found to be malignant on follow-up. We analyzed data from two cohorts of participants undergoing low-dose CT screening. The development data set included participants in the Pan-Canadian Early Detection of Lung Cancer Study (PanCan). The validation data set included participants involved in chemoprevention trials at the British Columbia Cancer Agency (BCCA), sponsored by the U.S. National Cancer Institute. The final outcomes of all nodules of any size that were detected on baseline low-dose CT scans were tracked. Parsimonious and fuller multivariable logistic-regression models were prepared to estimate the probability of lung cancer. In the PanCan data set, 1871 persons had 7008 nodules, of which 102 were malignant, and in the BCCA data set, 1090 persons had 5021 nodules, of which 42 were malignant. Among persons with nodules, the rates of cancer in the two data sets were 5.5% and 3.7%, respectively. Predictors of cancer in the model included older age, female sex, family history of lung cancer, emphysema, larger nodule size, location of the nodule in the upper lobe, part-solid nodule type, lower nodule count, and spiculation. Our final parsimonious and full models showed excellent discrimination and calibration, with areas under the receiver-operating-characteristic curve of more than 0.90, even for nodules that were 10 mm or smaller in the validation set. Predictive tools based on patient and nodule characteristics can be used to accurately estimate the probability that lung nodules detected on baseline screening low-dose CT scans are malignant. (Funded by the Terry Fox Research Institute and others; ClinicalTrials.gov number, NCT00751660.)

21 February 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MTMartin C. Tammemägi
Martin C. Tammemägi
HKHormuzd A. Katki
Hormuzd A. Katki
WHWilliam G. Hocking
William G. Hocking
TCTimothy Robert Church
Timothy Robert Church
NCNeil Caporaso
Neil Caporaso
CBChristine D. Berg
Christine D. Berg
The National Lung Screening Trial (NLST) used risk factors for lung cancer (e.g., ≥30 pack-years of smoking and <15 years since quitting) as selection criteria for lung-cancer screening. Use of an accurate model that incorporates additional risk factors to select persons for screening may identify more persons who have lung cancer or in whom lung cancer will develop. We modified the 2011 lung-cancer risk-prediction model from our Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to ensure applicability to NLST data; risk was the probability of a diagnosis of lung cancer during the 6-year study period. We developed and validated the model (PLCOM2012) with data from the 80,375 persons in the PLCO control and intervention groups who had ever smoked. Discrimination (area under the receiver-operating-characteristic curve [AUC]) and calibration were assessed. In the validation data set, 14,144 of 37,332 persons (37.9%) met NLST criteria. For comparison, 14,144 highest-risk persons were considered positive (eligible for screening) according to PLCOM2012 criteria. We compared the accuracy of PLCOM2012 criteria with NLST criteria to detect lung cancer. Cox models were used to evaluate whether the reduction in mortality among 53,202 persons undergoing low-dose computed tomographic screening in the NLST differed according to risk. The AUC was 0.803 in the development data set and 0.797 in the validation data set. As compared with NLST criteria, PLCOM2012 criteria had improved sensitivity (83.0% vs. 71.1%, P<0.001) and positive predictive value (4.0% vs. 3.4%, P=0.01), without loss of specificity (62.9% and. 62.7%, respectively; P=0.54); 41.3% fewer lung cancers were missed. The NLST screening effect did not vary according to PLCOM2012 risk (P=0.61 for interaction). The use of the PLCOM2012 model was more sensitive than the NLST criteria for lung-cancer detection.

1 February 2014 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
EPEdward F. Patz
Edward F. Patz
PPPaul Pinsky
Paul Pinsky
CGConstantine Gatsonis
Constantine Gatsonis
JSJoRean D. Sicks
JoRean D. Sicks
BKBarnett S. Kramer
Barnett S. Kramer
FTfor the NLST Overdiagnosis Manuscript Writing Team
for the NLST Overdiagnosis Manuscript Writing Team
Screening for lung cancer has been proposed for decades. It is fundamentally based on the principle that tumors will be detected at a smaller size and earlier stage, when treatment is more effective, resulting in a reduction in lung cancer mortality.1,2 An ideal screening program targets individuals at the highest risk of lung cancer, uses a cost-effective test to detect tumors at an early stage, and efficiently excludes patients with clinically insignificant abnormalities.

18 July 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SKStephanie A. Kovalchik
Stephanie A. Kovalchik
MTMartin Tammemagi
Martin Tammemagi
CBChristine D. Berg
Christine D. Berg
NCNeil E. Caporaso
Neil E. Caporaso
TRTom L. Riley
Tom L. Riley
HKHormuzd A. Katki
Hormuzd A. Katki
In the National Lung Screening Trial (NLST), screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung-cancer mortality among participants between the ages of 55 and 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since quitting. It is not known whether the benefits and potential harms of such screening vary according to lung-cancer risk. We assessed the variation in efficacy, the number of false positive results, and the number of lung-cancer deaths prevented among 26,604 participants in the NLST who underwent low-dose CT screening, as compared with the 26,554 participants who underwent chest radiography, according to the quintile of 5-year risk of lung-cancer death (ranging from 0.15 to 0.55% in the lowest-risk group [quintile 1] to more than 2.00% in the highest-risk group [quintile 5]). The number of lung-cancer deaths per 10,000 person-years that were prevented in the CT-screening group, as compared with the radiography group, increased according to risk quintile (0.2 in quintile 1, 3.5 in quintile 2, 5.1 in quintile 3, 11.0 in quintile 4, and 12.0 in quintile 5; P=0.01 for trend). Across risk quintiles, there were significant decreasing trends in the number of participants with false positive results per screening-prevented lung-cancer death (1648 in quintile 1, 181 in quintile 2, 147 in quintile 3, 64 in quintile 4, and 65 in quintile 5). The 60% of participants at highest risk for lung-cancer death (quintiles 3 through 5) accounted for 88% of the screening-prevented lung-cancer deaths and for 64% of participants with false positive results. The 20% of participants at lowest risk (quintile 1) accounted for only 1% of prevented lung-cancer deaths. Screening with low-dose CT prevented the greatest number of deaths from lung cancer among participants who were at highest risk and prevented very few deaths among those at lowest risk. These findings provide empirical support for risk-based targeting of smokers for such screening. (Funded by the National Cancer Institute.)

4 March 2014 in Annals of Internal Medicine
Verified
Journal Article
Closed access
HKHarry de Koning
Harry de Koning
RMRafael Meza
Rafael Meza
SPSylvia K. Plevritis
Sylvia K. Plevritis
KHKevin Ten Haaf
Kevin Ten Haaf
VMVidit N. Munshi
Vidit N. Munshi
PMPamela M. McMahon
Pamela M. McMahon
This comparative modeling study provides estimates of the benefits and harms of computed tomography screening for lung cancer in persons aged 45 through 90 years with various pack-year exposures to... Background: The optimum screening policy for lung cancer is unknown. Objective: To identify efficient computed tomography (CT) screening scenarios in which relatively more lung cancer deaths are av...

12 October 2005 in JAMA
Verified
Journal Article
Closed access
PDF file
CTC. Martin Tammemagi
C. Martin Tammemagi
DNDavid Nerenz
David Nerenz
CNChristine Neslund-Dudas
Christine Neslund-Dudas
CFCarolyn Feldkamp
Carolyn Feldkamp
DNDavid Nathanson
David Nathanson
Research from JAMA — Comorbidity and Survival Disparities Among Black and White Patients With Breast Cancer — ContextReasons for the shorter survival of black breast cancer patients compared with their white counterparts are not completely understood.ObjectiveTo evaluate the role of comorbidity in this racial disparity among breast cancer patients.Design, Setting, and PatientsHistorical cohort from the Henry Ford Health System (a large comprehensive health system in Detroit, Mich) followed up for a median of 10 years. Patients (n = 906) included 264 black (29.1%) and 642 white (70.9%) women diagnosed as having breast cancer between 1985 and 1990. Detailed comorbidity data (268 comorbidities) and study data were abstracted from medical records and institutional, Surveillance, Epidemiology, and End Results, and Michigan State registries. Associations were analyzed with logistic and Cox regression.Main Outcome MeasuresBreast cancer recurrence/progression and survival to death from all, breast cancer, and competing (non–breast cancer) causes.ResultsOf blacks, 64 (24.9%) died of breast cancer and 95 (37.0%) died of competing causes. Comparable data for whites were 115 (18.3%) and 202 (32.1%). Blacks had worse all-cause survival (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.11-1.62), breast cancer–specific survival (HR, 1.47; 95% CI, 1.08-2.00), and competing-causes survival (HR, 1.27; 95% CI, 1.00-1.63). A total of 77 adverse comorbidities were associated with reduced survival. Adverse comorbidity count was associated with all-cause (adjusted HR, 1.29; 95% CI, 1.19-1.40) and competing-causes survival but was not associated with recurrence/progression or breast cancer–specific survival. At least 1 adverse comorbidity was observed in 221 (86.0%) blacks and 407 (65.7%) whites (odds ratio, 3.20; 95% CI, 2.17-4.72). Comparisons of unadjusted and comorbidity-adjusted HRs indicated that adverse comorbidity explained 49.1% of all-cause and 76.7% of competing-causes survival disparity. Diabetes and hypertension were particularly important in explaining disparity.ConclusionsMore black breast cancer patients die of competing causes than of breast cancer. Effective control of comorbidity in black breast cancer patients should help improve life expectancy and lead to a reduction in survival disparities.